Merck & Co to buy rights to heart drug; Rosetta Genomics Reports Preliminary Data on MicroRNA Print E-mail
By Staff and Wire Reports   
Tuesday, 26 July 2011 19:16
Below is a look at some of the headlines for companies that made news in the healthcare sector on July 26, 2011.

ASTELLAS PHARMA INC (PINK:ALPMY) said it had agreed to sell the North American rights to the intravenous form of atrial fibrillation drug vernakalant to Merck & Co., Inc. (NYSE:MRK) for an undisclosed sum on Wednesday.

Astellas said in a statement Merck will pay them an upfront fee and milestone payments associated with the development, regulatory approval and sales in Canada, Mexico and the United States.


Rosetta Genomics Ltd. (NASDAQ:ROSGD)
announced preliminary data on MicroRNA Signature For Identification from a study it conducted in order to identify a microRNA signature in blood for congestive heart failure (HF) syndrome and to assess the feasibility to develop a minimally-invasive, microRNA-based stratification test for HF.

Early identification of patients at higher risk for adverse events could lead to earlier intervention that could potentially improve outcomes.

Demographic and clinical status of HF patients in combination with indices of cardiac and renal function can identify a large proportion of high risk patients, however, risk stratification based on these factors alone remains imprecise, with some high risk patients not recognized and others inappropriately marked as high risk.

In this proof of concept (POC) study, expression levels of a wide panel of microRNA were measured in the sera of stable chronic systolic HF patients and controls.

The differences in microRNA expression between the two groups were characterized and a score, based on the levels of the 4 microRNAs with the significant increase in the HF group, was defined.

Also Tuesday:

Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) is pleased to provide a summary of its second poster presentation at the Alzheimer's Association International Conference (AAIC) held in Paris, entitled "Preclinical development of new tetrahydrofuran derivatives targeting the sigma-1 chaperone protein as neuroprotectants in Alzheimer's disease."

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced completion of its Phase 3 study with AEZS-130 as the first oral diagnostic test for Adult Growth Hormone Deficiency (AGHD).

Caliper Life Sciences, Inc. (NASDAQ:CALP) announced today that its new, innovative LabChip® Dx instrument has achieved CE IVD registration in Europe.

Cambrex Corporation (NYSE:CBM) announced that second quarter 2011 financial results will be released on Tuesday, August 2, 2011 after the market closes.

Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology company, today announced that it will report its financial results for the second quarter ended June 30, 2011 after market close on Thursday, August 4, 2011 and will host a conference call at 5:00 p.m. Eastern Time to discuss those financial results.

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will host a conference call on Monday, August 8th, 2011, at 8:30 AM ET, to discuss its financial results for the second quarter of 2011.

InspireMD, Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), the developer of the MGuard™ mesh protective stent system, announced today that the first patient has been enrolled in the MASTER (MGuard for Acute ST Elevation Reperfusion) Randomized Trial, a multinational randomized controlled trial designed to demonstrate MGuard Coronary Stent's superiority over standard care for STEMI (heart attack) patients.

Neogen Corporation (NASDAQ:NEOG) announced today that net income for its 2011 fiscal year, which ended May 31, increased 30% from the previous year to $22,839,000.

Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has closed the acquisition of Paddock Laboratories, Inc. ("Paddock"), a privately-held, Minneapolis-based pharmaceutical manufacturer of generic Rx pharmaceuticals and OTC specialty products for approximately $540 million in cash.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has submitted a Premarket Approval Application (PMA) to the U.S. Food and Drug Administration (FDA) for the Elecsys Anti-HBc IgM assay for use on the cobas e 411, cobas e 601 and MODULAR ANALYTICS E170 analyzers.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced today that the European Medicines Agency (EMA) accepted for evaluation Vanda's Marketing Authorization Application (MAA) for oral iloperidone tablets.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus